You are here

  • Home
  • Archive
  • Volume 10, Issue 9
  • Correction: Emerging NK cell therapies for cancer and the promise of next generation engineering of iPSC-derived NK cells

Article Text

Article menu

See original article:

Download PDFPDF

Correction
Correction: Emerging NK cell therapies for cancer and the promise of next generation engineering of iPSC-derived NK cells

https://doi.org/10.1136/jitc-2022-004693corr1

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Maddineni S, Silberstein JL, Sunwoo JB. Emerging NK cell therapies for cancer and the promise of next generation engineering of iPSC-derived NK cells. J Immunother Cancer 2022;10:e004693. doi:10.1136/jitc-2022-004693

    In the section titled 'Induced pluripotent stem cell-derived NK cell therapies', The sentence 'For instance, CAR-NK cells derived from iPSCs targeting mesothelin showed strong in vivo responses in mouse A1847 ovarian cancer and outperformed PB-NK cell therapy' has had the phrase 'mouse A1847 ovarian cancer' updated to 'human A1847 ovarian cancer'.